This is a single-arm, multi-cohort, multicenter, phase Ib/IIa clinical study designed to evaluate the safety and efficacy of Zeprumetostat (an EZH2 inhibitor) in combination with different therapeutic agents/regimens - specifically, the JAK1 inhibitor golidocitinib and the GemOx chemotherapy regimen (gemcitabine plus oxaliplatin) - in patients with relapsed or refractory peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and T-follicular helper cell lymphoma (TFHL). The trial comprises a phase Ib dose-escalation phase and a phase IIa dose-expansion phase. Two combination cohorts are established: Cohort A (zemitostatin + golidocitinib) and Cohort B (zemitostatin + GemOx). Subjects will be randomly assigned to either Cohort A or Cohort B.
Age 18 years or older, both males and females are eligible;
Patients who have undergone prior hematopoietic stem cell transplantation are allowed;
ECOG PS 0-2
Life expectancy greater than 3 months.
Prior treatment with EZH2 inhibitors or EZH1/2 inhibitors before enrollment;
Peripheral T-cell lymphoma of subtypes other than PTCL-NOS and TFHL;
History of other primary invasive malignancies that have not been in remission or have been in remission for no more than 3 years;
Central nervous system involvement (meningeal or parenchymal);